Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04144439

Effect of GABA on ADHD and Seizures in Children With Epilepsy.

Effect of GABA on ADHD and seizures in Children with epilepsy.

Recruiting

Interested in participating?

Request Info

Key information

Age range

4 year–18 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Sherief Abd-Elsalam

Tanta, 35111, Egypt

Location status: Recruiting

Location contact

Abeer Salamah, Msc

CONTACT

00201009221243

About this study

Effect of Gamma aminobutyric acid on ADHD and seizures in Children with epilepsy.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Epilepsy
  • ADHD

Exclusion criteria

  • Epilepsy without ADHD

Treatment and study plan

GABA

Drug

Gamma amino butyric acid

Other names: Gamma amino butyric acid

Primary outcomes

  1. Number of seizures

    Time frame: 6 months

    Number of seizures

Study contacts

Contact information is provided by the study sponsor or research team.

Sherief Abd-Elsalam, ass. prof.

CONTACT

[email protected]

00201147773440

sherief abd-elsalam, ass. prof.

CONTACT

[email protected]

00201147773440

Sponsors and collaborators

Lead sponsor

Sherief Abd-Elsalam

Other

Registry information

Official study title

Effect of Gamma Aminobutyric Acid on ADHD and Seizures in Children With Epilepsy.

Important dates

Study start
2018
Primary completion
2028
Study completion
2028
First posted
Oct 30, 2019
Registry last updated
Oct 30, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.